drugset / Trial / NCT02779114

RETRO (REduction of Therapy in RA Patients in Ongoing Remission)

NCT02779114

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 3, multicenter, randomized, open, prospective, controlled, parallel-group intervention study in 318 patients with Rheumatoid Arthritis. The study is composed of 3 phases: a pre-randomization phase for up to 10 days followed by a 1-year randomized, open three arm treatment phase for each patient, followed by a 5-year observational phase for all patients still in remission.

Timeline

Start
2009-01
Primary completion
2017-12
Completion
2018-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified
Subject Adalimumab Monoclonal antibody
Subject Azathioprine Small molecule
Subject Certolizumab Protein / enzyme biologic
Subject Cyclosporine Peptide
Subject Etanercept Protein / enzyme biologic
Subject Golimumab Monoclonal antibody
Subject Hydroxychloroquine Small molecule
Subject Infliximab Monoclonal antibody
Subject Leflunomide Small molecule
Subject Methotrexate Small molecule
Subject Mycophenolate Mofetil Small molecule
Subject Sulfasalazine Small molecule
Subject Tocilizumab Monoclonal antibody

Indications